List view / Grid view
High throughput screening is mostly done in pharmaceutical companies that test whole libraries of compounds. Reducing the assay volume will reduce operating costs. At the same time it is necessary to prove that the smaller volume will not have a negative impact on assay sensitivity and reliability.
ELRIG’s (European Laboratory Research & Innovation Group) Drug Discovery meeting, will take place at ExCeL, London, UK, located in the heart of the city, from 9 -10 October 2018...
Takara Bio has played a major role in the development of single-cell genomics with the launch of kits such as the automation-ready Smart-seq HT, with a simplified 4-steps protocol. In addition, to meetthe demand for using RNA-seq for degraded clinical samples, we have expanded our offering with a complete sequencing…
This webinar shines a spotlight on cell-based and biochemical high-throughput screening in 1536 well plates. Supported by BMG LABTECH, the webinar will take place on 30 October at 4:00pm (GMT).
Flow cytometry is a powerful and flexible technology that delivers high content information from single cells and particles. Flow cytometry lends itself to a wide variety of applications, but traditional flow cytometry technologies are not widely adopted in the drug discovery industry due to limited throughput, slow sampling speeds and…
Flow cytometry has become a widely used technology in life science research since its development in the 1970s. It is also essential for many biopharmaceutical and biotechnology companies due to its proficiency in identifying biomarkers, finding new inhibitory antibodies, and assessing the efficiency of new pharmacological protocols.
Explore the full kinetic and epitope diversity of large antibody libraries with high throughput Array SPR (Surface Plasmon Resonance).
In this In-Depth Focus: upstream cell culture processes for the production of therapeutic proteins, the evolving role of three-dimensional in-vitro cell culture techniques in drug discovery, and human iPSCs-derived functional cells are revolutionising phenotypic drug discovery and development.
For many years, screening assays have been based on high-content imaging systems. However, recent advances in the field of flow cytometry have meant that flow-based assays are now more prevalent. The power of flow cytometry to utilise multiple lasers, multiple fluorochromes and multiplexed assays has meant that assays are not…
Biologics are the fastest growing class of therapeutics in the biopharmaceutical industry. A key driver for this growth is success with anti-cancer immunotherapeutics such as checkpoint modulation, adoptive cell therapy and bispecific T-cell engagers. While these approaches use different tactics to attack tumours, they often employ monoclonal antibodies to target…
Drug discovery is a lengthy process that proceeds through several stages. High throughput screening (HTS) utilising whole-cell based screening assays play a fundamental role as a starting point for identifying novel compounds in the drug discovery process.1,2
How times change. Up to 15 years ago, you would be hard-pressed to find a drug discovery conference with a track dedicated to phenotypic approaches. The underpinning science was called high-content imaging or analysis, being mainly confined to academic drug discovery labs and a handful of pioneers in industry. but…
15 June 2018 | By IntelliCyt
The Intellicyt Mouse IgG Type and Titer Kit is a high throughput, multiplexed assay kit that enables analyses of isotype, titer and cell health in a single assay...
The demand for new therapeutics is driving efforts to discover novel antibodies and harness their power in both biologics and adoptive cell therapy areas.
